A recent study indicates that individuals who discontinue new slimming jabs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who end conventional diet and exercise regimens.
Published data in a major health publication demonstrates that while overweight people frequently drop a large proportion of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using such treatments need to be cognizant of the potential of quick weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about a year and a half.
Comparing Treatments
The research, which looked at 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
The team note that people who lose weight through diet and exercise usually have a less rapid creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Doctors propose the way of the jabs explains the accelerated weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, due to the high risk of weight regain, the therapy is often long-term.
This view is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Experiences
People who have discontinued the jabs explain a intense return of hunger.
"I experienced a switch flipping and you become ravenous," described an individual.
This difficulty is worsened if users have not established permanent dietary or behavioural changes during treatment.
Growing Use
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is greater among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone fix and lasting health benefits hinges on combined lifestyle support.